ExodusPoint Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

ExodusPoint Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,690	Closed	-$246K	–	1730
2024 Q1	$246K	Buy	+17,690	New	+$153K	﹤0.01%	1307
2023 Q3	–	Sell	-6,316	Closed	-$34K	–	1902
2023 Q2	$34K	Buy	+6,316	New	+$50.9K	﹤0.01%	1785
2022 Q4	–	Sell	-4,462	Closed	-$92K	–	1859
2022 Q3	$92K	Buy	+4,462	New	+$114K	﹤0.01%	1753
2022 Q2	–	Sell	-5,187	Closed	-$223K	–	2163
2022 Q1	$223K	Sell	5,187 -2,767	-35%	-$125K	﹤0.01%	1867
2021 Q4	$476K	Buy	+7,954	New	+$637K	﹤0.01%	1447
2021 Q3	–	Sell	-5,711	Closed	-$635K	–	2365
2021 Q2	$635K	Buy	5,711 +3,094	+118%	+$297K	0.01%	1232
2021 Q1	$291K	Buy	2,617 +96	+4%	+$12.6K	﹤0.01%	1697
2020 Q4	$268K	Buy	+2,521	New	+$336K	﹤0.01%	1594

Other funds holding INO

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

ExodusPoint Capital Management's INO Position: Q2 2024 in Review

ExodusPoint Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2024, closing a stake of 17,690 shares — an estimated $246K sold.

ExodusPoint Capital Management first reported a position in INO in Q4 2020 and held it in 8 quarters. The position peaked at $635K in Q2 2021. 96 funds tracked by Wall St. Rank hold INO as of Q2 2024.

ExodusPoint Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 17,690 Inovio Pharmaceuticals shares in Q2 2024, an estimated $246K.
ExodusPoint Capital Management first reported a position in Inovio Pharmaceuticals in Q4 2020 and held it in 8 quarters.
ExodusPoint Capital Management's Inovio Pharmaceuticals position peaked at $635K in Q2 2021.
96 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2024.

Based on ExodusPoint Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.